Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

February 19, 2013  6:00 – 8:30 p.m.

1. **Executive Session**  6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes**  6:30 - 6:35
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates**  6:35 - 6:45
   - Updates

4. **Medical Director Update**  6:45 - 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. **Follow-up Items from Previous Meetings**  6:45 - 7:00
   - Skeletal Muscle Relaxants
   - Gastrointestinal: Anti-ulcer: H.Pylori Combination Therapy

6. **RetroDUR/DUR**  7:00 – 7:30
   - Methadone for Chronic Pain
   - Narcotic Analgesics – continued use of short acting with no long acting

7. **Clinical Update: Drug Reviews**  7:30 – 7:55
   (Public comment prior to Board action)
   - Abbreviated New Drug Reviews
     - Gelnique® 3% (oxybutynin 3% gel) 84 mg/3 pump actuations
     - Rectiv® (nitroglycerin 0.4%) Topical Ointment
     - Sorilux® (calcipotriene 0.005%) Topical Foam
   - Full New Drug Reviews
     - Myrbetriq® (mirabegron) Extended Release Tablet
     - Tudorza® Pressair (aclidinium bromide) Dry Powder Inhaler
8. Therapeutic Drug Classes – Periodic Review 7:55 – 8:20
   (Public comment prior to Board action)
   **Class review documents available on DVHA web site 02/19/2013 @ 12 Noon**
   - Antiemetics – 5HT3 Receptor Antagonists & Neurokinin 1 Receptor Antagonist
   - Antiemetics - Delta-9-Tetrahydrocannabinol (THC) Derivatives
   - Benign Prostatic Hyperplasia Agents
   - Erythropoiesis Stimulating Agents
   - Ophthalmic Alpha-Agonists
   - Ophthalmic Carbonic Anhydrase Inhibitors
   - Urinary Antispasmodics

9. New Managed Therapeutic Drug Classes 8:20 – 8:20
   (Public comment prior to Board action)
   - None

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:20 – 8:20
    (Public comment prior to Board action)
    - None

11. General Announcements 8:20– 8:30
    **Selected FDA Safety Alerts**
    - Samsca® (tolvaptan): Drug Warning - Potential Risk of Liver Injury
    - Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

12. Adjourn 8:30